The aim of the study was to assess the capabilities of mRNA genes encoding CD16a (FCGR3A) and CD16b (FCGR3B) proteins in tumor samples from patients with renal cancer, and characterize the tumor process in relation to clinical and morphological factors. Here, FCGR3B is linked to neoplasm.